RC88 Gets Fast Track Designation for Gynecologic Cancer Treatment

The FDA granted a Fast Track Designation to RC88, a novel antibody-drug conjugate, to treat patients with platinum-resistant gynecologic cancers.

Related Keywords

Jianmin Fang ,Drug Administration ,Remegen Co ,Fast Track Designation ,Antibody Drug Conjugates ,Patients With ,Investigational New Drug ,Gynecologic Cancer ,